Clinical trial
Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia…
NCT00210119 · Institut Bergonié, Other · Terminated
Key facts
| NCT number | NCT00210119 |
|---|---|
| Title | Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response |
| Official title | Multicentric Phase II Study to Evaluate Feasibility and Efficacy of Association of Imatinib Mesylate and Zoledronic Acid in Patients With Chronic Myeloid Leukaemia in Cytogenetic Response Without Molecular Response After One Year of Imatinib Mesylate Monotherapy |
| Acronym | AFR22 |
| Lead sponsor | Institut Bergonié, Other |
| Collaborators | Novartis Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myeloid Leukemia, Chronic |
| Intervention type | Drug |
| Interventions | Glivec |
| Enrollment | 19 |
| Start date | Jul 12, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Mar 1, 2009 |
| First posted | Sep 21, 2005 |
| Last update posted | Nov 8, 2021 |
| Countries | France |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: